Primary Hyperoxaluria Type 1 (PH1), Cardiovascular (CV)
European Renal Association (ERA) 2026
Congress Details
June 3-6, 2026
Glasgow, Scotland
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Agenda
Filters
Therapeutic Areas
04 June, 2026
Presentation Type
Time
Location
Title
Presenter
Wesley Hayes
Zurich Childrens Hospital,
Zurich, Switzerland
Presentation Type
Time
Location
Title
Presenter
David Wheeler
University College London, UK
05 June, 2026
Presentation Type
Time
Location
Title
Presenter
Yaacov Frishberg
Shaare Zedek Medical Center
Jerusalem, Israel
Presentation Type
Time
Location
Title
Presenter
Sander Garrelfs
Amsterdam UMC
Amsterdam, Netherlands
Related Materials
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial
Frontiers in Pediatrics
